Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) (R01 Clinical Trial Not Allowed)
ID: 353243Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $4M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353243

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-010.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Feasibility of Novel Diagnostics for TB in Endemic Countries" (FEND for TB), aimed at enhancing tuberculosis (TB) diagnostics in regions where the disease is prevalent. This initiative seeks to evaluate early-stage diagnostic tests and strategies, particularly those targeting vulnerable populations such as people living with HIV, while adhering to existing clinical algorithms. The total funding available for this opportunity is approximately $5.5 million, anticipated to support 1-2 awards over a five-year period, with applications due by June 29, 2024. Interested applicants can find more information and submit their proposals electronically through Grants.gov, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-010-Full-Announcement.html
    RFA-AI-24-010.html
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Feasibility of Novel Diagnostics for TB in Endemic Countries" (FEND for TB) to enhance tuberculosis (TB) diagnostics in countries where TB is prevalent. The aim is to evaluate early-stage diagnostic tests and strategies, including those targeting specific populations like people living with HIV. This funding opportunity (RFA-AI-24-010) is open for applications from eligible organizations, with a total of $5.5 million anticipated for 1-2 awards over five years. The applications must propose innovative early-stage technologies and include detailed evaluation plans, along with demonstrating collaboration with clinical sites in endemic areas. Critical topics of interest include point-of-care diagnostics, non-sputum specimen analysis, and rapid drug susceptibility testing. Applications will not be considered if they involve clinical trials or the establishment of new clinical infrastructure. The review process will evaluate the significance, innovation, and approach of the proposed projects. Eligible applicants include a broad range of institutions and organizations, including higher education institutions, non-profits, and foreign organizations. All applications must comply with NIH guidelines and be submitted electronically through Grants.gov, with a due date of June 29, 2024.
    Similar Opportunities
    Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Tuberculosis (R01 Clinical Trial Not Allowed)." This initiative aims to solicit research applications focused on the preclinical development of lead candidate vaccines to combat Mycobacterium tuberculosis (Mtb) infection and disease, thereby enhancing the clinical pipeline of viable vaccine candidates. The program is critical for advancing public health efforts against tuberculosis, a significant global health challenge. The estimated total funding for this program is $4,730,000, with approximately five awards expected. Interested applicants can reach out to Katrin Eichelberg, MSc, PhD, at keichelberg@nih.gov or call 240-669-2921 for further information. Key deadlines include an estimated synopsis post date of September 8, 2025, and a close date of November 7, 2025, with awards anticipated to be made by July 1, 2026.
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Strengthening tuberculosis (TB) prevention, diagnosis, and treatment in Southeast Asia to end TB
    Centers for Disease Control-GHC
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement aimed at strengthening tuberculosis (TB) prevention, diagnosis, and treatment in Southeast Asia, with a focus on reducing TB burden and mortality in high-burden countries. The initiative seeks to implement innovative approaches to enhance early TB diagnosis, advance TB prevention interventions, and improve treatment outcomes for individuals affected by TB, including those with drug-resistant strains. This funding opportunity, with an estimated total of $10 million for the first fiscal year, is open to unrestricted applicants, and interested parties can reach out to the CDC at pepfarfoas@cdc.gov for further information. Applications must be submitted electronically by 11:59 PM ET on February 17, 2026, with awards expected to be announced by September 30, 2026.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R01 Clinical Trial Not Allowed)" aimed at supporting research into the immunometabolic changes induced by HIV that may elevate the risk of tuberculosis (TB) and hepatitis B virus (HBV) in individuals on combination antiretroviral therapy (cART). This initiative seeks to fund investigator-led studies that explore the long-term effects of HIV-related alterations in immune metabolism on disease progression and treatment responses, with a focus on identifying biomarkers and innovative therapies to mitigate these risks. The grant is open to a wide range of eligible applicants, including higher education institutions, non-profits, and for-profit organizations, with no cost-sharing requirements. Interested parties should note that the application submission deadlines range from April 2025 to January 2028, and they can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For further details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-25-315.html.
    Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Elucidating Immunometabolic Responses to HIV Infection that Increase TB or HBV Risk," aimed at supporting research into the immunometabolic changes induced by HIV in individuals undergoing combination antiretroviral therapy. This initiative seeks to investigate how these alterations affect immune responses and increase the risk of subsequent infections, specifically tuberculosis (TB) and hepatitis B virus (HBV). The funding opportunity is particularly significant for advancing understanding in the field of HIV-related health risks and aims to foster innovative research approaches, including the use of machine learning and AI to identify biomarkers and therapeutic targets. Eligible applicants can receive up to $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-316.html.
    Infectious Diseases Clinical Trials Network (IDCTN)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Infectious Diseases Clinical Trials Network (IDCTN)" aimed at advancing public health through the rapid implementation of clinical trials for infectious diseases. This initiative seeks to establish a network comprising Clinical Trial Evaluation Units (CTEUs) and a Network Coordination Center (NCC) to evaluate therapeutics, vaccines, diagnostics, and devices, addressing urgent public health needs that standard grant timelines cannot meet. With an estimated total program funding of $29 million, this opportunity is open to a wide range of eligible applicants, including Indian/Native American Tribal Governments, federal agencies, and community-based organizations. Interested parties can reach out to Dr. Marina S. Lee at 240-627-3304 or via email at dmidclinicaltrials@niaid.nih.gov for further information, with key deadlines including an estimated synopsis close date of June 11, 2026, and an anticipated award date of March 1, 2027.
    Strengthening comprehensive HIV and TB services and health systems in high-burden areas of Namibia under the President's Emergency Plan for AIDS Relief (PEPFAR)
    Centers for Disease Control-GHC
    The Centers for Disease Control and Prevention (CDC) is offering a cooperative agreement to strengthen comprehensive HIV and TB services and health systems in high-burden areas of Namibia under the President's Emergency Plan for AIDS Relief (PEPFAR). The initiative aims to enhance facility- and community-based service delivery for HIV, TB, and associated comorbidities, while supporting the Ministry of Health and Social Services (MOHSS) in overseeing government-led programs, including case management and public health response. This funding opportunity, with an estimated total of $14 million for the first fiscal year, is open to unrestricted applicants, and interested parties should submit their applications electronically by February 17, 2026, to be considered for the anticipated awards, which are expected to be announced by September 30, 2026. For further inquiries, applicants can contact the grantor at pepfarfoas@cdc.gov.
    Implementation Science to End the HIV Epidemic
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Implementation Science to End the HIV Epidemic," aimed at advancing efforts to combat HIV through innovative research-community collaborations. The initiative seeks projects that will develop and evaluate strategies for HIV prevention, diagnosis, treatment, and outbreak response, particularly in communities disproportionately affected by the epidemic. This funding, totaling an estimated $7 million, will support approximately 10 awards, with applications open to a diverse range of eligible entities, including tribal governments, federal agencies, and community-based organizations. Interested applicants should note that the estimated synopsis close date is April 17, 2026, and the anticipated award date is December 1, 2026; for further inquiries, contact Rebecca Mandt, Ph.D., at rebecca.mandt@nih.gov or call 301-435-7695.
    Advancing TB Prevention, Detection and Treatment in the Philippines
    Philippines USAID-Manila
    USAID/Philippines is forecasting a cooperative agreement opportunity titled "Advancing TB Prevention, Detection and Treatment in the Philippines," aimed at eliminating tuberculosis (TB) in the country. The initiative seeks to partner with capable local organizations, including NGOs, universities, and consortiums, that have experience in infectious disease projects, particularly TB, to contribute to a future five-year project with an estimated funding of $25 million. This project is critical for enhancing health outcomes in the Philippines, addressing a significant public health challenge. Interested organizations can find more information and submission requirements on the USAID/Philippines website or contact Ma. Belinda De La Torre at +63-2-301-4927 or via email at ROAA-Admin-Manila@usaid.gov for further inquiries.
    Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity titled "Priority HIV/AIDS Research" under the R01 grant mechanism. This initiative aims to stimulate research that aligns with NIH’s priorities regarding HIV/AIDS, particularly focusing on systemic complications such as metabolic, gastrointestinal, and kidney issues arising from HIV, while encouraging the incorporation of health-impeding social determinants of health into research proposals. The anticipated funding amount is $2 million, with plans to support 3 to 5 awards over five years, and applications are due starting May 7, 2025. Interested applicants can find more information and application guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.